STOCK TITAN

Braveheart Bio: Forbion funds report 12.9%, 11.3% stakes

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Forbion Growth Opportunities Fund III Cooperatief U.A. reported direct ownership of 11,640,546 shares of Braveheart Bio, Inc. (BRVE), approximately 12.9%; Forbion Ventures Fund VII Cooperatief U.A. reported direct ownership of 10,185,478 shares, approximately 11.3%. Their respective management companies may be deemed to have voting and investment power over the shares held by their associated funds, so those positions are not additional share blocks. The percentages are based on 90,038,969 common shares outstanding as of September 3, 2026.

Shares beneficially owned 11,640,546 shares Directly owned by Forbion Growth Opportunities Fund III Cooperatief U.A.
Ownership percentage 12.9% Forbion Growth Opportunities Fund III Cooperatief U.A.; based on shares outstanding as of September 3, 2026.
Shares beneficially owned 10,185,478 shares Directly owned by Forbion Ventures Fund VII Cooperatief U.A.
Ownership percentage 11.3% Forbion Ventures Fund VII Cooperatief U.A.; based on shares outstanding as of September 3, 2026.
Common shares outstanding 90,038,969 shares As of September 3, 2026, as reported by Braveheart Bio.
beneficially owned regulatory
"Amount beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Shared Voting Power regulatory
"Shared Voting Power 11,640,546.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
Shared Dispositive Power regulatory
"Shared Dispositive Power 11,640,546.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BRVE shares do the Forbion funds own?

Forbion Growth Opportunities Fund III Cooperatief U.A. reported direct ownership of 11,640,546 BRVE common shares, approximately 12.9%, and Forbion Ventures Fund VII Cooperatief U.A. reported direct ownership of 10,185,478 shares, approximately 11.3%. Their respective management companies may be deemed to share voting and investment power over the same fund-held shares; those manager-reported positions are not additional blocks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





10567X101

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Forbion Growth Opportunities Fund III Cooperatief U.A.
Signature:/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:Directors of its Director
Date:11/16/2026
Forbion Growth III Management B.V.
Signature:/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:Directors
Date:11/16/2026
Forbion Ventures Fund VII Cooperatief U.A.
Signature:/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:Directors of its Director
Date:11/16/2026
Forbion Ventures VII Management B.V.
Signature:/s/ G.J Mulder and /s/ M.A. van Osch
Name/Title:Directors
Date:11/16/2026

Keep reading